PULM
Pulmatrix·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PULM
Pulmatrix, Inc.
A clinical-stage biopharmaceutical company that developing innovative inhaled therapies to treat and prevent the spread of infectious and progressive respiratory diseases
945 Concord Street, Suite 1217, Framingham, MA 01701
--
Pulmatrix, Inc., incorporated in Nevada on January 18, 2013, is a wholly-owned subsidiary of Oculus Innovative Sciences, Inc. The Company is a clinical-stage biopharmaceutical company focused on the development of novel inhalation therapy products designed to prevent and treat respiratory and diseases with important unmet medical needs using the patented iSPERSE technology. The Company's proprietary product pipeline includes the treatment of central nervous system diseases such as acute migraine and severe lung diseases such as chronic obstructive pulmonary disease and allergic bronchopulmonary aspergillosis. The company's product candidates are based on the proprietary engineered dry powder delivery platform iSPERSE, which is designed to improve treatment delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes.
Company Financials
EPS
PULM has released its 2025 Q3 earnings. EPS was reported at -0.24, versus the expected 0, missing expectations. The chart below visualizes how PULM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
